Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 192,700 shares, a drop of 6.4% from the September 30th total of 205,900 shares. Based on an average trading volume of 535,500 shares, the days-to-cover ratio is presently 0.4 days. Approximately 1.3% of the company’s shares are sold short.

Aptose Biosciences Stock Performance

Shares of APTO stock opened at $0.38 on Friday. The company’s 50 day moving average price is $0.39 and its two-hundred day moving average price is $0.70. Aptose Biosciences has a 52 week low of $0.33 and a 52 week high of $3.32.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.15.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of Aptose Biosciences in a research note on Monday. They set a “hold” rating on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $9.00.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences as of its most recent SEC filing. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.